Dianthus Therapeutics (NASDAQ:DNTH) Announces Earnings Results, Beats Estimates By $0.04 EPS

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04, Zacks reports. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%.

Dianthus Therapeutics Stock Down 3.9 %

Dianthus Therapeutics stock traded down $0.96 during midday trading on Tuesday, reaching $23.38. 299,958 shares of the stock traded hands, compared to its average volume of 226,001. Dianthus Therapeutics has a 12 month low of $18.13 and a 12 month high of $33.77. The stock's fifty day moving average is $22.56 and its 200-day moving average is $25.02. The stock has a market cap of $691.98 million, a P/E ratio of -9.35 and a beta of 1.82.

Wall Street Analyst Weigh In

Several research firms recently commented on DNTH. TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a "buy" rating on the stock. Oppenheimer raised their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, November 11th. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Finally, Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $46.83.

Remove Ads

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.